banner
FLT3 inhibitor TG-101348, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ422

FLT3 inhibitor TG-101348, Purity ≥98%

Synonym: Fedratinib; 936091-26-8; Tg-101348; TG101348; SAR302503; SAR-302503; N-(tert-Butyl)-3-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide; FLT3 inhibitor

  • MDL: MFCD12922515
  • CAS Number: 936091-26-8
  • Compound CID: 16722836
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
TG-101348, soluble in DMSO and insoluble in ethanol and water, is a protein tyrosine kinase inhibitor that has shown potent biochemical activity against FLT3. It targets FLT3, JAK2, JAK2 (V617F), and RET.
Molecular Weight
524.7
Molecular Formula
C27H36N6O3S
Targets
FLT3: 15 nM; JAK2: 3 nM; JAK2 (V617F): 3 nM; RET: 48 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 90 mg/mL (171.53 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
TG-101348 can be employed to study its JAK2 inhibition in myeloproliferative neoplasm research.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0